Long-term rates of cardiovascular events in patients with the metabolic syndrome according to severity of coronary-angiographic alterations

Coronary Artery Disease

Volumn 20, Issue 1, 2009, Pages 1-8

  Solymoss, Bela C ^a   Bourassa, Martial G ^a   Marcil, Michel ^b   Levesque, Sylvie ^a   Varga, Susan ^c   Campeau, Lucien ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c Westmount Medical Clinic   (Canada)

Author keywords

Cardiovascular risk factors; Coronary artery disease; Metabolic syndrome; Mortality; Myocardial infarction; Stroke

Indexed keywords

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; PRIORITY JOURNAL; STROKE;

EID: 58149265222     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32831624a5     Document Type: Article

References (23)

1. Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven GM. Relationship between degree of obesity and in vivo insulin action in men. Am J Physiol 1985; 248:E286-E291.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
3. Reaven GM. Syndrome X: 6 years later. J Int Med 1994; 236 (Suppl 736):13-22.
4. Alberti KG, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
5. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285:2486-2497.
6. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Circulation 2005; 112:e285-e290.
7. Alberti KG, Zimmet P, Shaw J; for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancer 2005; 366:1059-1062.
8. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death. A systematic review and meta-analysis of longitudinal studies. J Am Coll Card 2007; 49:403-414.
9. Solymoss BC, Bourassa MG, Lesperance J, Levesque S, Marcil M, Varga S, Campeau L Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease. Coron Art Dis 2003; 14:207-212.
10. Ninth International Classification of Diseases. Geneva. WHO Chron 1978; 32:219-225.
11. Anthonisen NR Database research. Can Resp J 2005; 12:241-242.
12. Rawson NS, Malcolm E. Validity of recording of ischemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care data files. Stat Med 1995; 14:2627-2643.
13. Schillacci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43:1817-1822.
14. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415-1428.
15. Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opinion Lipidol 2007; 18:263-270.
16. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 2005; 6:7-14.
17. Amano T, Matsubara T, Uetani T, Nanki M, Marui N, Kato M, et al. Impact of metabolic syndrome on tissue characteristics of angiographically mild to moderate lesions integrated backscatter intravascular ultrasound study. J Am Coll Card 2007; 49:1149-1156.
18. Campbell CY, Nasir K, Blumenthal RS. Metabolic syndrome, subclinical atherosclerosis, and cardiovascular risk. Am Heart Hosp J 2005; 3:105-110.
19. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Slonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:2709-2716.
20. Marroquin OC, Kip KE, Kelley DE, Johnson BD, Shaw LJ, Bairey Merz CN, et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation 2004; 109:714-721.
21. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110:1245-1250.
22. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lindl L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006; 332:878-882.
23. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stem MP; San Antonio Heart Study. National cholesterol education program versus World Health Organization metabolic syndrome in relation all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110:1251-1257.